With 24 years of experience as a Medical Oncologist, my primary focus is to deliver “convergence sciences”- based solutions to deliver precision medicine in cancer. I am actively involved in multiple NIH (five-active) grants as a Multi-PI, conducting research that fuse ultra-sensitive bio-engineering technologies with omic-based devices to develop molecular evidence-based algorithms that may potentially tackle unanswered challenges of cancer medicine, regardless of the clinical context which may range from novel therapeutic molecule discovery and drug development to molecular biomarkers of standard drugs.

I have held various roles from leading as Director of Personalized Medicine Institutes in several cancer centers to conducting individualized medicine clinical trials. I have obtained several patents in precision medicine as well. Presently, I hold the position of Professor (tenured on joining) in the Department of Medicine and the Jack Presidential Endowed Chair at the University of Utah-Huntsman Cancer Institute in cancer research.

The need to bring different sciences together and to dedicate a multi-disciplinary approach for providing individualized patient care in the field of cancer in my focus. At the same time, I recognize that this achievement has to be cost-effective, to which end I work, collaborate and publish with a team of health economics outcome researchers (HEOR) in caner medicine.

As advancements in biological sciences and computing have progressed rapidly our on-going multi-disciplinary team science grant projects determine novel approaches to develop in silico multi-omic, machine learning and augmented intelligence platforms and algorithms that can be included unto innovative clinical trial designs as well as drug development.